Mind Medicine (MindMed) Inc. Common Shares (MNMD) Dividend History

Mind Medicine (MindMed) Inc. (MNMD) is a biotech company focused on developing psychedelic-inspired medicines and therapies for mental health and neurological conditions. It explores novel compounds and digital therapeutics aimed at addressing challenges such as anxiety, addiction, depression, and attention deficit disorders. The company emphasizes research into the therapeutic potential of psychedelics and related compounds to improve mental well-being.

One World Trade Center, New York, NY, 10007
Phone: 212-220-6633
Website: https://www.mindmed.co

Dividend History

Mind Medicine (MindMed) Inc. Common Shares currently does not pay dividends

Company News

  • Why Mind Medicine Stock Is Skyrocketing Today

    Mind Medicine's stock is surging after Robert F. Kennedy Jr. was confirmed as the new U.S. Health and Human Services secretary. Kennedy has previously voiced support for psychedelics as therapeutic treatments, which could benefit Mind Medicine's drug development efforts.

    The Motley Fool
  • 5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

    The 5-HT2 agonist pipeline is robust, with over 20 pharmaceutical companies actively developing 22+ pipeline drugs. Advancements in precision medicine and personalized approaches are driving the market, enabling selective targeting of receptor subtypes and improving safety and efficacy.

    GlobeNewswire Inc.
    Featured Companies: ATAI CYBN HRMY RVPH
  • 4 Psychedelic Stocks to Consider as Clinical Trials Heat up

    Several biotechnology firms have psychedelic treatments in development, with promising results from clinical trials. The psychedelic market is expected to grow significantly, and most investors are favorable towards psychedelic stocks.

    Investing.com
    Featured Companies: ATAI
  • Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?

    Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.

    Zacks Investment Research
    Featured Companies: RMD
  • Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment

    A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.Some members of the panel, ...Full story available on Benzinga.com

    Benzinga
    Featured Companies: ATAI CYBN PSIL
Page data last updated 07/23/2025 08:03:29 UTC